08:03 AM EST, 12/04/2024 (MT Newswires) -- Theratechnologies ( THTX ) said Wednesday it acquired exclusive Canadian rights to two investigational RNA-targeted medicines from Ionis Pharmaceuticals ( IONS ) .

The agreement includes olezarsen, which is being evaluated for familial chylomicronemia syndrome and severe hypertriglyceridemia, and donidalorsen, which is being studied for hereditary angioedema treatment.

Theratechnologies ( THTX ) will pay Ionis $10 million upfront, with potential milestone payments of up to $12.75 million and tiered double-digit royalties on net sales.

The company said it would oversee regulatory approvals in Canada while Ionis would remain the primary manufacturer. The agreement extends until commercialization ceases or upon earlier termination.